Hepatitis C - Innovations to Advance Elimination
Nov
13
2023
Grand Ballroom
-
Sheraton Boston Hotel
8:30
- 10:00 AM EST
Description
Abstracts
- LONG-TERM RISK OF LIVER-RELATED AND NON-LIVER-RELATED DEATH AFTER DIRECT-ACTING ANTIVIRAL-MEDIATED SUSTAINED VIROLOGIC RESPONSE IN HEPATITIS C VIRUS PATIENTS
- ONGOING EXPERIENCE OF IMPLEMENTING "THE TORONTO PROTOCOL": AN ULTRA-SHORT COURSE GLECAPRIVER/PIBRENTASVIR WITH EZETIMIBE FOR SOLID ORGAN TRANSPLANTATION FROM HCV-INFECTED DONORS TO HCV-UNINFECTED RECIPIENTS
- HEALTHCARE ACCESS THROUGH FACILITATED TELEMEDICINE FOR UNDERSERVED POPULATIONS: A STEPPED WEDGE CLUSTER RANDOMIZED CONTROLLED TRIAL OF HEPATITIS C VIRUS TREATMENT AMONG PERSONS WITH OPIOID USE DISORDER
- LOW ANTIVIRAL TREATMENT RATE FOR PATIENTS WITH HEPATITIS C (HCV)-RELATED HEPATOCELLULAR CARCINOMA (HCC)– A REAL-WORLD NATIONWIDE U.S. STUDY
- ESTABLISHING A PHARMACIST-LED HEPATITIS C TREATMENT CLINIC WITHIN A LARGE HEALTHCARE SYSTEM
- CHARACTERIZING LINKAGE TO HEPATITIS C VIRUS CARE DURING AND FOLLOWING PREGNANCY: IDENTIFYING MISSED OPPORTUNITIES FOR TESTING AND TREATMENT